Mark Cuban warns that patenting work makes it public, allowing any AI model to train on it instantly. To maintain a competitive data advantage, he suggests companies should increasingly rely on trade secrets, keeping their valuable IP out of the public domain and away from competitors' models.

To speed up IP licensing from a university, founders should avoid advisors known for aggression. Instead, hire an experienced, solution-oriented advisor who already has a good relationship with the tech transfer office. They won't waste time creating bad will over impossible demands.

Elizabeth Jeffords shares a Genentech adage for biotech growth: give away your first and possibly second product via licensing deals. This strategy, which Iolyx followed, provides crucial non-dilutive capital and validation, building a foundation to eventually commercialize a third asset independently.

Oshkosh structures partnerships to own IP developed jointly with a startup, then licenses it back. This approach, outlined in the initial NDA, gives the large corporation control over patent defense while providing the startup with usage rights, often with market-specific limitations.

Dan Schmitt used his role as an Entrepreneur in Residence at Northwestern University to gain priority access to new technologies. This strategic position allowed him to secure the foundational asset for Actuate Therapeutics, directly bridging academic innovation with commercial enterprise.

A key driver of Sweden's entrepreneurial biotech culture is a law allowing inventors, such as university professors, to personally own the patents from their research. This contrasts with the US model where institutions retain IP rights, giving Swedish academics a direct incentive to commercialize their discoveries.

Institutional ownership of intellectual property can stifle a clinician's motivation to commercialize their idea. Dr. Adam Power advocates for an 'inventor-owned' IP model, arguing that no university department or tech transfer office will ever match the round-the-clock drive of the inventor themself.

Biotech companies are incentivized to own the entire intellectual property for a drug, from delivery to molecule. This leads to endless litigation and siloed innovation, preventing the combination of "best-in-class" components from different companies and ultimately slowing progress for patients.

Moving technology from academia to a startup requires a crucial mindset shift. The academic goal of publishing data must be replaced by the industry requirement of extensive validation. For Vivtex, this single piece of advice added years of work but was essential for creating a commercially viable platform.